Skip to main content
Clinical Trials/NCT04724954
NCT04724954
Completed
N/A

Arm Motor Rehabilitation, Entertainment and Cognition System for the Elderly

Bright Cloud International Corp2 sites in 1 country6 target enrollmentMarch 1, 2019
ConditionsAcute Stroke

Overview

Phase
N/A
Intervention
Not specified
Conditions
Acute Stroke
Sponsor
Bright Cloud International Corp
Enrollment
6
Locations
2
Primary Endpoint
Change in Fugl-Meyer Assessment score for upper extremity function (UE sub-set)
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

The research project is intended to provide information pertaining to the usability, feasibility and clinical benefit of the BAC system for early sub-acute post CVA rehabilitation, improved cognition and emotive state while in acute inpatient rehabilitation settings (Kessler Foundation) and in an outpatient clinic at the same research hospital.

The randomised controlled trials will take place at Kessler Foundation (West Orange, NJ). It will develop a new longitudinal therapy for elderly stroke survivors who are inpatients and then outpatients at a regional rehabilitation hospital, by adding BAC training to customary care for both inpatients and outpatients. Two systems will be used, improving continuity of care (one each for inpatient and outpatient settings).

Detailed Description

This study targets participants, who had suffered a stroke very recently, who may or may not have been diagnosed with mild cognitive impairments or dementia (including Alzheimer's disease). It is important to find out if these improvements can be obtained with the computer game-based integrative (motor-cognitive) bimanual rehabilitation developed by Bright Cloud International Corp, and if these gains transfer to daily activities. The study also aims at determining benefit of continuum care training on the BAC in addition to conventional rehabilitation for participants who are inpatients and then outpatients at a rehabilitation hospital and clinic. Specific aims are: BAC technology acceptance (all groups); improved motor function for upper extremity; strengthening shoulder and fingers increased range of motion for arms and fingers; improved independence in activities of daily living; improved cognition; improved emotive state; reduction in perceived upper body pain. Another component of the research project is a small pilot targeting individuals with Parkinson's disease. For them the project is going to: determine technology acceptance when using the BrightBrainer system; benefit to arms motor function and strengthening when playing BCI therapeutic games; benefit to reduction or tremor when playing games; cognitive benefits improvement in their well-being.

Registry
clinicaltrials.gov
Start Date
March 1, 2019
End Date
December 31, 2019
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Grigore Burdea

Chief Technology Officer

Bright Cloud International Corp

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Change in Fugl-Meyer Assessment score for upper extremity function (UE sub-set)

Time Frame: Change between baseline, at 3 weeks and at 5 weeks post enrollment

Upper Extremity Mobility and function. It is scored from 0 (minimum score) to 66 (maximum). The higher the score, the better, with 66 indicating normal upper extremity function.

Change in Cognitive executive function assessment score

Time Frame: Change between baseline, at 3 weeks and at 5 weeks post enrollment

Trail Making Test B (TMT-B), Neuropsychological Assessment Battery (NAB) Executive Functioning Module. This is a timed test (seconds) with less time indicative of better executive function. No scale.

Secondary Outcomes

  • Change in Upper extremity functional index (UEFI-20) of independence in activities of daily living(Change between baseline, at 3 weeks and at 5 weeks post enrollment)
  • Change in Verbal attention as measured by the Neuropsychological Assessment Battery(Change between baseline, at 3 weeks and at 5 weeks post enrollment)
  • Change in Arm Range of Motion(Change between baseline, at 3 weeks and at 5 weeks post enrollment)
  • Change in Grasp strength for whole hand (power grasp) and finger pinch(Change between baseline, at 3 weeks and at 5 weeks post enrollment)
  • Change in Finger Range of Motion measured with mechanical goniometer(Change between baseline, at 3 weeks and at 5 weeks post enrollment)
  • Change in CAHAI 9 Score of independence in bimanual ADLs(Change between baseline, at 3 weeks and at 5 weeks post enrollment)
  • Game % Score (baseline and performance) in therapeutic games(through study completion, an average 5 weeks from enrollment)
  • Change in Beck Depression Inventory II (BDI II) score, a measure of depression severity(Change between baseline, at 3 weeks and at 5 weeks post enrollment)
  • Change in Stroke Impact Scale (SIS) measuring impact of stroke on independence in daily activities(Change between baseline, at 3 weeks and at 5 weeks post enrollment)
  • Game difficulty levels(through study completion, an average 5 weeks from enrollment)
  • Average game difficulty levels per session(through study completion, an average 5 weeks from enrollment)
  • Participants' feedback through subjective evaluation of the system(at 3 weeks and at 5 weeks post enrollment)
  • Change in visual attention as measured by Neuropsychological Assessment Battery(Change between baseline, at 3 weeks and at 5 weeks post enrollment)
  • Caregiver evaluation of experimental system(at 5 weeks from enrolment)

Study Sites (2)

Loading locations...

Similar Trials